Guido M. Dalbagni

Guido M. Dalbagni's AcademicInfluence.com Rankings

Guido M. Dalbagni

Medical

#3217

World Rank

#3675

Historical Rank

Epidemiology

#611

World Rank

#636

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Guido M. Dalbagni Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Guido M. Dalbagni's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Epidemiology and risk factors of urothelial bladder cancer. (2013) (1625)
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. (2009) (1151)
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. (2007) (815)
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. (1993) (536)
Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. (2015) (450)
Cystectomy for bladder cancer: a contemporary series. (2001) (441)
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. (1992) (345)
Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder (2006) (341)
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. (2003) (338)
Age‐adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer (2008) (272)
p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns (1994) (268)
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. 1 1 H. Barton Grossman, M.D (2002) (260)
Genetic alterations in bladder cancer (1993) (252)
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes (2014) (246)
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. (2002) (239)
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. (2009) (234)
Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. (1997) (229)
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. (2017) (225)
Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. (2010) (215)
Standardization of pelvic lymphadenectomy performed at radical cystectomy (2006) (215)
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. (2015) (207)
Metastatic renal cell carcinoma risk according to tumor size. (2009) (201)
A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder (2008) (194)
Deletion of the p16 and p15 genes in human bladder tumors. (1995) (194)
Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. (1994) (189)
Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. (2004) (189)
Genomic Characterization of Upper Tract Urothelial Carcinoma. (2015) (183)
Defining bacillus Calmette-Guerin refractory superficial bladder tumors. (2003) (183)
Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. (2011) (182)
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. (2007) (174)
Comparative genomic analysis of tumors: detection of DNA losses and amplification. (1995) (172)
Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. (2018) (169)
Urothelial Carcinoma of the Renal Pelvis: A Clinicopathologic Study of 130 Cases (2004) (164)
Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle‐invasive and non‐organ confined disease in patients with upper tract urothelial carcinoma (2012) (162)
Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. (1994) (158)
Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. (2002) (156)
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. (2010) (152)
Editorial comment on: detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. (2010) (149)
Contemporary use of partial nephrectomy at a tertiary care center in the United States. (2009) (148)
Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. (2004) (147)
Male urethral carcinoma: analysis of treatment outcome. (1999) (145)
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma (2018) (135)
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer (2016) (135)
Urachal carcinoma: contemporary surgical outcomes. (2007) (135)
Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. (1996) (134)
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? (2007) (119)
Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. (2012) (119)
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. (2009) (117)
Impact of a second transurethral resection on the staging of T1 bladder cancer. (2002) (114)
Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? (2010) (113)
Carcinoma in a bladder diverticulum: presentation and treatment outcome. (2003) (113)
The impact of re‐transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high‐grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin (2016) (110)
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. (2006) (110)
The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. (2017) (108)
Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. (2003) (104)
Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. (2012) (102)
Molecular Genetic Alterations of Chromosome 17 and p53 Nuclear Overexpression in Human Bladder Cancer (1993) (101)
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. (2018) (98)
Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Are Overexpressed in Squamous Cell Carcinoma of the Penis (2004) (98)
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. (2008) (98)
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. (2019) (96)
Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. (2004) (94)
Nested Variant of Urothelial Carcinoma: A Clinicopathologic and Immunohistochemical Study of 12 Cases (2003) (92)
Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. (2006) (90)
Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. (1999) (89)
Transitional cell carcinoma of the bladder in young adults: presentation, natural history and outcome. (2002) (87)
Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. (2012) (84)
Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy. (1998) (83)
Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. (2008) (81)
Somatic mutation of fibroblast growth factor receptor‐3 (FGFR3) defines a distinct morphological subtype of high‐grade urothelial carcinoma (2011) (81)
Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters. (2012) (80)
Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. (2004) (80)
Pathological response to neoadjuvant chemotherapy for muscle‐invasive micropapillary bladder cancer (2013) (79)
Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. (2004) (78)
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. (2003) (74)
Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. (2000) (72)
Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. (2011) (71)
Prospective evaluation of MRI, ¹¹C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. (2012) (70)
Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer (2006) (70)
Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? (2004) (65)
Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. (1994) (63)
Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder. (2013) (62)
Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. (1997) (61)
Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. (1999) (60)
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. (2016) (60)
Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. (2003) (56)
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. (2010) (55)
The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. (2017) (55)
Genetic studies and molecular markers of bladder cancer. (1997) (54)
Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma (2005) (54)
Risk factors for the development of parastomal hernia after radical cystectomy. (2013) (54)
Narrow‐band imaging cystoscopy to evaluate bladder tumours – individual surgeon variability (2009) (54)
BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. (2015) (52)
Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. (2019) (51)
Safety and efficacy of intravesical bacillus Calmette-Guérin instillations in steroid-treated and immunocompromised patients. (2006) (50)
Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer (2006) (49)
Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder (2007) (47)
Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. (2002) (46)
Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy? (1999) (45)
Reflex UroVysion testing in suspicious urine cytology cases (2009) (44)
Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma (2014) (44)
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. (2013) (42)
Management of Postoperative Lymphoceles After Lymphadenectomy: Percutaneous Catheter Drainage With and Without Povidone-Iodine Sclerotherapy (2013) (42)
Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma. (2012) (42)
The anterior layer of Denonvilliers' fascia: a common misconception in the laparoscopic prostatectomy literature. (2007) (42)
Overview of bladder cancer trials in the Cancer and Leukemia Group B (2003) (40)
Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer (2012) (40)
Glutathione S-transferase P1 Ile105Val polymorphism, cigarette smoking and prostate cancer. (2004) (39)
P53 nuclear overexpression and disease progression in ta-bladder carcinoma. (1993) (39)
Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer (1996) (39)
Role of voided urine cytology in diagnosing primary urethral carcinoma. (2004) (38)
The management of superficial bladder cancer (2007) (38)
Clinical outcome of primary versus secondary bladder carcinoma in situ. (2010) (37)
Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer. (2013) (37)
A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. (2016) (37)
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. (1997) (35)
Preoperative accuracy of diagnostic evaluation of the urachal mass. (2012) (35)
Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy (2014) (34)
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. (2016) (34)
Intravesical bacille Calmette‐Guérin (BCG) in immunologically compromised patients with bladder cancer (2013) (33)
Contemporary management of penile cancer: greater than 15 year MSKCC experience. (2014) (33)
Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings (2014) (32)
The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm. (2016) (32)
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought (2018) (31)
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology (2019) (31)
Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. (2001) (31)
Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma (2013) (30)
Natural history of positive urinary cytology after radical cystectomy. (2006) (29)
The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery (2011) (29)
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. (2017) (28)
Management of bladder cancer after renal transplantation. (2013) (27)
Genetic alterations associated with bladder cancer. (1994) (26)
Clinical benefits of a multivariate prediction model for bladder cancer (2009) (25)
Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. (2001) (25)
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. (2020) (25)
Chromosome 16 in primary prostate cancer: A microsatellite analysis (1997) (24)
Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. (2009) (24)
Postoperative nomogram for disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to American Joint Committee on Cancer staging classification. (2014) (24)
Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. (2010) (23)
Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder (2017) (23)
Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis (2006) (23)
Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection (2013) (23)
INTRATUMORAL HETEROGENEITY OF ERBB2 AMPLIFICATION AND HER2 EXPRESSION IN MICROPAPILLARY UROTHELIAL CARCINOMA: MP48‐03 (2017) (23)
Update on intravesical agents for non-muscle-invasive bladder cancer. (2010) (22)
Cigarette smoking and chromosome 9 alterations in bladder cancer. (1997) (22)
Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development. (2004) (22)
Tumor suppressor gene alterations in bladder carcinoma. Translational correlates to clinical practice. (1995) (21)
External beam radiation therapy for small cell carcinoma of the urinary bladder. (2015) (21)
The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer (2014) (21)
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia (2021) (19)
A plea for a uniform surveillance schedule after radical cystectomy. (2011) (18)
[Cyclooxygenase inhibitors]. (2001) (17)
The impact of fluid optimisation before induction of anaesthesia on hypotension after induction (2020) (17)
Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. (2006) (17)
Urinary diversion practice patterns among certifying American urologists. (2012) (17)
Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC). (2012) (16)
Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion? (2017) (16)
Cooperative Effects of p 53 and pRB Alterations in Primary Superficial Bladder Tumors ' (2006) (16)
Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort. (2021) (16)
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. (2020) (15)
Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience (2014) (15)
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer (2021) (14)
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy (2018) (14)
Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC) (2007) (14)
[Arachidonic acid and prostaglandins, inflammation and oncology]. (2001) (14)
Radical cystectomy and orthotopic urinary reconstruction in patients with bladder cancer after renal transplantation: clinical outcomes and description of technique. (2013) (13)
Sequential adjuvant chemotherapy after surgical resection of high‐risk urothelial carcinoma (2009) (13)
Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma (2010) (13)
Comparison of bladder cancer survival among Japanese, Chinese, Filipino, Hawaiian and Caucasian populations in the United States. (2003) (13)
Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. (2017) (13)
Utility of Routine Preoperative 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18F-FDG PET/CT) in Identifying Pathologic Lymph Node Metastases at Radical Cystectomy. (2020) (13)
Adherence to surveillance guidelines after radical cystectomy: a population-based analysis. (2014) (12)
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers (2021) (12)
Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063) (2017) (12)
RISK OF METASTATIC RENAL CELL CARCINOMA ACCORDING TO TUMOR SIZE (2009) (11)
Trends in Management and Outcomes Among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. (2020) (11)
Intraoperative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication Rates. (2020) (11)
Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscleinvasive and non-organ confined disease in patients with upper tract urothelial carcinoma (2011) (11)
Goal-directed versus Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy: A Prospective Randomized Controlled Trial. (2020) (11)
Bladder cancer in cystoscopically normal‐appearing mucosa: a case of mistaken identity? (2010) (11)
274: Phase II Trial of Intra Vesical Gemcitabine in BCG-Refractory Transitional Cell Carcinoma of the Bladder (2004) (11)
Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer? (2009) (11)
Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC). (2016) (11)
Results of laparoscopic pelvic lymphadenectomy in patients at high risk for nodal metastases from prostate cancer (1998) (10)
Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy (2011) (10)
Preoperative Nutritional Status and The Impact on Radical Cystectomy Recovery: An International Comparative Study. (2016) (10)
Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle‐invasive Bladder Cancer (2017) (10)
THE IMPACT OF POSTOPERATIVE COMPLICATIONS ON THE TIMING OF ADJUVANT CHEMOTHERAPY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR INVASIVE OR NODE POSITIVE BLADDER CANCER (BCa) (2008) (9)
Implementing a Multimodal Prehabilitation Program to Radical Cystectomy in a Comprehensive Cancer Center: A Pilot Study to Assess Feasibility and Outcomes. (2019) (9)
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma (2021) (9)
Comparative study between cytology and dot-ELISA for early detection of bladder cancer. (1996) (9)
Bladder cancer: Restaging TUR reduces recurrence and progression risk (2010) (9)
Carcinoma of the pancreas in nonjaundiced patients. A silent disease. (1985) (8)
Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND. (2014) (8)
1235: Prostate Involvement by Urothelial and Prostatic Carcinomas in Radical Cystoprostatectomy Specimens (2006) (8)
Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract. (2006) (8)
Non-squamous cell carcinoma of the penis: single-center, 15-year experience (2014) (8)
Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution (2016) (8)
Idiographic quality of life assessment before radical cystectomy (2017) (7)
Goal-directed versus Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy. (2020) (7)
Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy (2019) (7)
PACLITAXEL(T), ESTRAMUSTINE(E) AND CARBOPLATIN(C) IN PATIENTS (Pts) WITH ADVANCED PROSTATE CANCER(PC): (1999) (7)
Bladder cancer: advances in biology and treatment. (1994) (7)
Cell surface differentiation antigens of normal urothelium and bladder tumors. (1992) (7)
Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC). (2016) (7)
Critical review of biomarkers for the early detection and surveillance of bladder cancer (2009) (6)
Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer. (2020) (6)
Erratum: Clinical benefits of a multivariate prediction model for bladder cancer: A decision analytic approach (Cancer (2009) 115 (5460-5469)) (2011) (6)
Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. (2018) (6)
Two cases of spontaneous remission of non-parasitic chyluria. (2017) (6)
The prevalence of persistent prostate cancer after radiotherapy detected at radical cystoprostatectomy for bladder cancer. (2014) (5)
Targeted sequencing of upper tract urothelial carcinoma. (2014) (5)
Splenosis mimicking transitional cell carcinoma. (1999) (5)
Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes Following Radical Cystectomy. (2019) (5)
Formal sacrocolpopexy reduces hypercontinence rates in female neobladder formation (2018) (5)
Primary urethral cancer: treatment patterns and associated outcomes (2020) (5)
Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence (2017) (5)
Experience with potency preservation during radical prostatectomy. Significance of learning curve. (1988) (5)
LBA-17 MULTICENTER PROSPECTIVE PHASE II CLINICAL TRIAL OF GEMCITABINE AND CISPLATIN AS NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA (2019) (4)
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer (2021) (4)
The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum (2018) (4)
MP38-14 IMPLEMENTING A MULTIMODAL PREHABILITATION PROGRAM IN A HIGH-VOLUME BLADDER CANCER CENTER (2016) (3)
Prognostication of upper tract urothelial carcinoma: what do we really need? (2010) (3)
Examining the Accuracy of Self-Reported Smoking-Related Exposure Among Recently Diagnosed Non-muscle Invasive Bladder Cancer Patients. (2020) (3)
Clinical follow-up in 24 nonfamilial renal tumors cytogenetically characterized in tissue culture. (1994) (3)
639 PREOPERATIVE PREDICTORS OF RENAL FUNCTION DECLINE FOLLOWING RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA (2012) (3)
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma (2023) (3)
Previous history of bladder cancer as a prognostic factor for patients diagnosed with transitional cell carcinoma of the upper urinary tract (2004) (3)
Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma (2018) (3)
Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma. (2022) (3)
1001 The impact of re-TUR on clinical outcomes in a large cohort of t1g3 patients treated with BCG (2014) (3)
Beyond BCG: Gemcitabine (2009) (3)
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy (2021) (3)
PD17-11 THE IMPACT OF DIFFERENT BCG STRAINS ON OUTCOME IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG. (2015) (2)
Editorial comment on: The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? (2009) (2)
Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical instillations) of BCG Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer. (2021) (2)
Erratum: Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder (BJU International (2007) 99, 2, (281-285)) (2007) (2)
485 MULTI-INSTITUTIONAL QUALITY OF CARE INITIATIVE FOR NON-METASTATIC MUSCLE-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER: PHASE 1 (2011) (2)
Association of Biochemically Verified Post-Diagnosis Smoking and Nonmuscle-Invasive Bladder Cancer Recurrence Risk (2022) (2)
948 The impact of different BCG strains on outcome in a large cohort of T1G3 patients treated with BCG (2015) (2)
Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). (2022) (2)
Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC). (2018) (2)
PD47-07 UTILITY OF ROUTINE PREOPERATIVE 18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IN IDENTIFYING PATHOLOGIC LYMPH NODE METASTASES AT RADICAL CYSTECTOMY (2019) (2)
MP7-07 ENDOSCOPIC MANAGEMENT FOR UPPER TRACT UROTHELIAL CANCER (UTUC) COMPARED TO IMMEDIATE NEPHROURETERECTOMY: SURVIVAL OUTCOMES IN SEER DATABASE AND CANCER CENTER COHORT (2015) (2)
Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. (2019) (2)
RISK FACTORS FOR RESIDUAL DISEASE AT RE‐TUR IN T1G3 BLADDER CANCER: PD48‐03 (2017) (2)
MP55-04 PARTIAL CYSTECTOMY POST NEOADJUVANT CHEMOTHERAPY: MEMORIAL SLOAN-KETTERING CANCER CENTER CONTEMPORARY EXPERIENCE (2014) (2)
1697 PROGNOSTIC FACTORS AND RISK GROUPS IN T1G3 PATIENTS INITIALLY TREATED WITH BCG: RESULTS OF A MULTICENTER RETROSPECTIVE SERIES IN 2530 PATIENTS (2013) (2)
Next generation sequencing of urothelial bladder cancer: Memorial Sloan Kettering Cancer Center experience in 454 patients. (2018) (2)
Small cell carcinoma of the bladder (SCCB): Clinical, histopathologic, and genomic predictors of clinical outcomes. (2017) (2)
Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience. (2021) (1)
1226: Establishing a Minimum Number of Lymph Nodes to be Removed during Radical Cystectomy: Implications for the Necessary Extent of Dissection (2006) (1)
Effect of defective ERCC2 on cisplatin and ionizing radiation (IR) sensitivity in bladder cancer cells. (2017) (1)
2135 CONTEMPORARY MANAGEMENT OF RENAL TRANSPLANT PATIENTS DIAGNOSED WITH UROTHELIAL CARCINOMA OF THE BLADDER (2012) (1)
A phase I trial of chemoimmunotherapy combining bacillus Calmette-Guerin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade nonmuscle-invasive bladder cancer. (2021) (1)
MP06-01 INCIDENCE AND IMPACT OF VENOUS THROMBOEMBOLISM IN RADICAL CYSTECTOMY PATIENTS UNDERGOING PRE-OPERATIVE CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER (2016) (1)
MP60-12 MULTI-INSTITUTIONAL QUALITY CARE INITIATIVE TO IMPROVE THE CARE OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER (2014) (1)
DO CHANGES IN RENAL FUNCTION FOLLOWING NEPHROURETERECTOMY IMPACT THE USE OF PERIOPERATIVE CHEMOTHERAPY (2009) (1)
NEXT GENERATION SEQUENCING OF UROTHELIAL BLADDER CANCER: MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE IN 454 PATIENTS: MP54‐04 (2018) (1)
Nephroureterectomy at Memorial Sloan-Kettering Cancer Center (2010) (1)
The significance of ureteral sampling at radical cystectomy in bladder cancer patients (2005) (1)
Utility of Routine Preoperative 18F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.Reply. (2021) (1)
Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. (2022) (1)
PD11-10 A 10-ITEM CHECKLIST CHECKLIST IMPROVES REPORTING OF CRITICAL PROCEDURAL ELEMENTS DURING TRANSURETHRAL RESECTION OF BLADDER TUMOR (2016) (1)
PD47-03 CHARACTERIZING THE LANDSCAPE OF ACTIONABLE GENOMIC ALTERATIONS TO IDENTIFY OPPORTUNITIES FOR TARGETED THERAPY TRIALS IN PATIENTS WITH LOCALIZED BLADDER CANCER (2019) (1)
Intratumoral heterogeneity of ERBB2/HER2 expression in micropapillary urothelial carcinoma. (2017) (1)
Is ‘second-look’ (re-staging) transurethral resection of bladder tumours a new standard of care? (2011) (1)
1512: Age Adjusted Charlson Comorbidity Score is Associated with Treatment Decisions and Clinical Outcomes for Patients Undergoing Radical Cystectomy for Bladder Cancer (2007) (1)
852: Biological Behavior of Bladder Cancer in Patients Previously Treated with Radiation for Prostate Cancer (2005) (1)
Characterization of actionable genetic alterations to guide targeted therapy for metastatic urothelial carcinoma. (2019) (1)
Comparison of genomic alterations in bladder urothelial tumors with and without telomerase reverse transcriptase promoter mutation using a next-generation sequencing assay. (2017) (1)
TEACHING NON-LINEAR KINETICS IN THE LAB (1998) (1)
MP38-06 COMPARING LONG-TERM ONCOLOGIC OUTCOMES BETWEEN OPEN RADICAL CYSTECTOMY AND ROBOT-ASSISTED LAPAROSCOPIC RADICAL CYSTECTOMY: A RANDOMIZED CLINICAL TRIAL (2016) (1)
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. (2022) (1)
IMPACT OF PREVIOUS RADIOTHERAPY FOR PROSTATE CANCER ON CLINICAL OUTCOMES OF BLADDER CANCER PATIENTS (2009) (1)
Radical Cystectomy and Urinary Diversion after Renal Transplantation: 1866 (2012) (1)
847: Prospective Evaluation of P53 as a Prognostic Marker in T1 Transitional Cell Carcinoma (TCC) of the Bladder (2006) (1)
1258: Utility of Assessment of Ureteral Margins during Radical Cystectomy for Urothelial Cancer (2006) (1)
V497: The Vesicoprostatic Muscle: A Critical Landmark during Dissection of the Posterior Bladder Neck in Laparoscopic Radical Prostatectomy (2006) (1)
PD18-08 CAN MUSCLE−INVASIVE BLADDER CANCER BE PREDICTED IN PATIENTS WITH CLINICAL T1 DISEASE? (2014) (1)
Image-Guided Intensity Modulated Radiation Therapy (IMRT) for Bladder Cancer: Toxicity and Early Outcomes (2014) (1)
External beam radiotherapy for small cell carcinoma of the urinary bladder: The Memorial Sloan-Kettering experience. (2012) (1)
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. (2022) (1)
External beam radiotherapy and concurrent gemcitabine for muscle-invasive bladder cancer: Toxicities and early outcomes. (2016) (1)
MP56-12 UPPER TRACT RECURRENCE RISK BASED ON DRAINAGE METHOD FOR URETERAL OBSTRUCTION PRIOR TO RADICAL CYSTECTOMY (2022) (0)
MP38-07 URETHRAL MELANOMA – CLINICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS (2019) (0)
Reply from Authors re: Amnon Zisman. Laparoscopic Nephroureterectomy: Is It Always as Good as Open Nephroureterectomy? Eur Urol 2010;58:652–3 (2010) (0)
Male and Female Sexual Function and Dysfunction ; Andrology Re : Evaluating Sexual Function in Women after Radical Cystectomy as Treatment for Bladder Cancer (0)
Next generation sequencing of non-muscle invasive bladder cancer to reveal potential biomarkers and rational therapeutic targets. (2017) (0)
MP7-13 GENETIC SIGNATURES ARE ASSOCIATED WITH ADVERSE PATHOLOGIC AND CLINICAL OUTCOMES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (UTUC) (2015) (0)
PD12-09 INHERITED CANCER PREDISPOSITION GENE VARIANTS IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (2020) (0)
Current Prospects for the Use of Molecular Markers in Treatment of Bladder Cancer by Cystectomy or Bladder-Conserving Approaches (2001) (0)
Phase I/II: Intravesical Gemcitabine for Superficial Bladder Cancer and Its Nursing Implications (2011) (0)
749 Clinical outcome in patients with T1 micropapillary carcinoma of the bladder (2013) (0)
929 NEXT-GENERATION DEEP SEQUENCING IDENTIFIES RECURRENT AND TARGETABLE GENETIC ALTERATIONS IN HIGH GRADE BLADDER UROTHELIAL CARCINOMA (2013) (0)
MP60-16 THREE-MONTH PATIENT-REPORTED OUTCOMES AFTER OPEN VERSUS ROBOTIC RADICAL CYSTECTOMY: A RANDOMIZED CLINICAL TRIAL (2014) (0)
PD10-04 CHARACTERIZING MALE ERECTILE FUNCTION AFTER RADICAL CYSTECTOMY (2022) (0)
The efficacy of BCG Tice and BCG Connaught in a cohort of 2099 T1G3 non-muscle invasive bladder cancer patients (2017) (0)
PD9-11 PREDICTORS OF SYMPTOMATIC URETERO-ENTERIC ANASTOMOTIC STRICTURES AFTER RADICAL CYSTECTOMY AND URINARY DIVERSION (2015) (0)
Re: Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? (2007) (0)
81: Patterns of Recurrence after Nephroureterectomy for Transitional Cell Carcinoma of the Upper Urinary Tract (2005) (0)
MP82-07 TRENDS IN PERIOPERATIVE MANAGEMENT AND OUTCOMES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETECTOMY AT MEMORIAL SLOAN KETTERING CANCER CENTER (2020) (0)
TARGETING ERBB2 MUTATIONS IN UROTHELIAL CARCINOMA: MP48‐16 (2017) (0)
Chromosomal Abnormalities in Renal Tumors (1987) (0)
407: Time Course of Upper Tract Recurrence Following Radical Cystectomy for Urothelial Cancer (2007) (0)
692 UPPER TRACT IMAGING SURVEILLANCE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER (2013) (0)
874 COMBINING IMAGING AND URETEROSCOPY VARIABLES IN A PREOPERATIVE MULTIVARIABLE MODEL FOR PREDICTION OF MUSCLE-INVASIVE AND NON-ORGAN CONFINED DISEASE IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (2011) (0)
Prognostic factors and risk groups in T1G3 patients initially treated with BCG: Results of a multicenter retrospective series in 1743 patients (2013) (0)
MP57-10 CHARACTERIZATION OF MOLECULAR DIFFERENCES BETWEEN SMOKERS AND NON-SMOKERS WITH UROTHELIAL CARCINOMA (2019) (0)
MP56-16 THE IMPACT OF RE-TUR ON CLINICAL OUTCOMES IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG. (2014) (0)
PD12-12 PATIENT MATCHED GENOMIC ANALYSIS OF HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER SPECIMENS PRE- AND POST-BCG IMMUNOTHERAPY (2020) (0)
MP55-17 IS UROTHELIAL CARCINOMA WITH SARCOMATOID DIFFERENTIATION RESPONSIVE TO NEOADJUVANT CHEMOTHERAPY? (2020) (0)
OUTCOMES OF NESTED VARIANT OF UROTHELIAL CARCINOMA FOLLOWING RADICAL CYSTECTOMY: MP04‐12 (2017) (0)
442 SUBGROUPS OF BLADDER CANCER PATIENTS PRIOR TO RADICAL CYSTECTOMY: A CLUSTER ANALYSIS (2013) (0)
Abstract A14: Next-generation sequencing of Bacille Calmette-Guerin (BCG)-unresponsive tumors identifies actionable alterations for potential targeted therapy in non-muscle invasive bladder cancer (2020) (0)
MP61-04 CHARACTERIZATION AND DISTRIBUTION OF SOFT TISSUE AND LYMPH NODE RECURRENCES AFTER RADICAL CYSTECTOMY (2020) (0)
1782 THE ROLE OF IMMEDIATE RADICAL CYSTECTOMY IN THE TREATMENT OF PATIENTS WITH RESIDUAL T1 ON RESTAGING TRANSURETHRAL RESECTION (2012) (0)
Reply by Authors. (2020) (0)
What to do when bacillus Calmette‐Guérin fails (2015) (0)
1111: The Effect of Body Mass Index (BMI) on the Quality and Morbidity of Radical Cystectomy for Bladder Cancer (2005) (0)
PD47-04 SURGICAL AND ONCOLOGIC OUTCOMES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FROM 1995-2015: THE MEMORIAL SLOAN KETTERING EXPERIENCE (2019) (0)
1919: CT Urography for Surveillance Following Radical Cystectomy and Urinary Diversion (2004) (0)
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma (2023) (0)
1749 IMPROVED SURVIVAL INSPITE OF NO DECREASE IN THE INCIDENCE OF LYMPH NODE INVASION IN WOMEN RECEIVING SURGERY FOR BLADDER CANCER: TIME-DEPENDENT TRENDS (2012) (0)
928 CONTEMPORARY MANAGEMENT OF PENILE CANCER: 15 YEAR EXPERIENCE (2012) (0)
PD18-01 RADIOGRAPHIC PREDICTORS OF PATHOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA: RESULTS OF A PHASE 2 CLINICAL TRIAL (2020) (0)
MP63-08 CLINICAL AND GENOMIC RISK FEATURES OF HIGH GRADE T1 NON-MUSCLE INVASIVE BLADDER CANCER (2023) (0)
MP63-13 NEXT-GENERATION SEQUENCING REVEALS GENOMIC DIFFERENCES BETWEEN MALE AND FEMALE PATIENTS WITH UROTHELIAL CARCINOMA (2019) (0)
MP7-17 HISTOLOGICAL VARIANTS OF UPPER URINARY TRACT UROTHELIAL CARCINOMA: THE 18-YEAR MSKCC EXPERIENCE (2015) (0)
Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial (2023) (0)
MP11-16 USE OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (FDG PET/CT) TO PREDICT VIABLE LYMPH NODE METASTASES FOLLOWING PREOPERATIVE CHEMOTHERAPY FOR MUSCLE INVASIVE AND ADVANCED-STAGE BLADDER CANCER (2015) (0)
MP77-01 TARGETED SEQUENCING OF UPPER TRACT UROTHELIAL CARCINOMA (2014) (0)
Reply by Authors. (2020) (0)
MP77-20 FGFR3 MUTATION ASSOCIATES WITH IMPROVED CANCER SPECIFIC OUTCOME IN UPPER TRACT UROTHELIAL CARCINOMA (2014) (0)
Cancer Immunity 3:19 (2003)-ARTICLE (2003) (0)
1772 REFLEX FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) ASSAY FOR ATYPICAL URINARY CYTOLOGY IN BLADDER CANCER PATIENTS UNDERGOING SURVEILLANCE CYSTOSCOPY (2013) (0)
Urethral Melanoma – Clinical, Pathological and Molecular Characteristics (2022) (0)
Uretero‐enteric stricture outcomes: secondary analysis of a randomised controlled trial comparing open versus robot‐assisted radical cystectomy (2022) (0)
Commentary (Dalbagni): Current Management of Unusual Genitourinary Cancers (1999) (0)
PD52-09 LATE RECURRENCES FOLLOWING RADICAL CYSTECTOMY HAVE DISTINCT PROGNOSTIC AND MANAGEMENT CONSIDERATIONS (2019) (0)
Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought (2017) (0)
Previous history of bladder cancer as a prognostic factor for patients diagnosed with transitional cell carcinoma of the upper urinary tract. (2004) (0)
Ureteroenteric Stricture Outcomes: Secondary analysis of an RCT comparing open vs robotic cystectomy. (2022) (0)
PD39-11 THE OUTCOME OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER IN THE RETROPERITONEUM (2016) (0)
Impact of perioperative blood transfusion on oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. (2015) (0)
1899 LYMPH NODE POSITIVE BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY AND LYMPHADENECTOMY: EFFECT OF THE LEVEL OF NODE POSITIVITY (2012) (0)
261: Positive Urine Cytology without Histologic Evidence of Bladder Cancer: Clinical Impact on Recurrent Bladder Cancer and Extra Vesical Sites of Disease (2004) (0)
PHENOTYPIC‐GENOTYPIC CORRELATION OF TP53 AND RB1 IN UROTHELIAL CARCINOMA: MP48‐17 (2017) (0)
Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma (2022) (0)
Characterization of POLE-mutated (POLE+) urothelial carcinoma of the bladder and urinary tract (UC). (2017) (0)
PD39-02 EARLY OUTCOMES OF PROPHYLACTIC MESH PLACEMENT AT RADICAL CYSTECTOMY TO PREVENT PARASTOMAL HERNIAS (2016) (0)
1261: Risk Factors for Development of Metastatic Disease and Death in Female Patients Undergoing Radical Cystectomy (2006) (0)
Genitourinary Pathology (2016) (0)
PD42-06 DEFINING THE GENETIC EVOLUTION OF EPIGENETIC ALTERATIONS IN BLADDER CANCER (2020) (0)
PD60-11 PROGNOSTIC SIGNIFICANCE OF PERIVESICAL LYMPH NODE STATUS IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY (2020) (0)
PD39-06 COST DASHBOARDS FOR RADICAL CYSTECTOMY: ACCOUNTING FOR SURGEON COST VARIATION (2016) (0)
MP54-01 DISCORDANCE BETWEEN CLINICAL AND PATHOLOGIC CARCINOMA IN SITU FOR TURBT AND RADICAL CYSTECTOMY IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR BCG UNRESPONSIVE CLINICAL TRIAL DESIGN AND INTERPRETATION (2022) (0)
MP63-08 PHASE 3 RANDOMIZED TRIAL OF INTRAVENOUS MANNITOL VERSUS PLACEBO PRIOR TO RENAL ISCHEMIA DURING PARTIAL NEPHRECTOMY: IMPACT ON RENAL FUNCTIONAL OUTCOMES (2015) (0)
COMPARISON OF GENOMIC ALTERATIONS IN BLADDER UROTHELIAL TUMORS WITH AND WITHOUT TELOMERASE REVERSE TRANSCRIPTASE PROMOTER MUTATION USING A NEXT‐GENERATION SEQUENCING ASSAY: MP65‐15 (2017) (0)
MP16-12 INTEGRATED GENE EXPRESSION PROFILING AND TARGETED PANEL SEQUENCING TO IMPROVE TREATMENT SELECTION IN NON-MUSCLE INVASIVE BLADDER CANCER (2021) (0)
THE IMPACT OF PLASMACYTOID VARIANT HISTOLOGY ON SURVIVAL OF PATIENTS WITH UROTHELIAL CARCINOMA OF BLADDER AFTER RADICAL CYSTECTOMY: MP21‐20 (2017) (0)
1035 VARIABILITY OF TREATMENT SELECTION AMONG SURGEONS IN PATIENTS WITH CT1 UROTHELIAL CARCINOMA (2010) (0)
MP64-11 PROPHYLACTIC MESH PLACEMENT AT RADICAL CYSTECTOMY TO PREVENT PARASTOMAL HERNIAS: TECHNIQUE AND EARLY COMPLICATIONS (2015) (0)
MP64-19 THE NATURAL HISTORY OF NON-MUSCLE INVASIVE, NESTED VARIANT OF UROTHELIAL CARCINOMA (2015) (0)
Genomic determinants of nested variant urothelial carcinoma. (2020) (0)
IS RESTAGING TRANSURETHRAL RESECTION (TUR) NECESSARY IN PATIENTS WITH NON‐MUSCLE INVASIVE BLADDER CANCER (NMIBC) AND FOCAL LAMINA PROPRIA INVASION?: PD48‐01 (2017) (0)
External beam radiotherapy for small cell carcinoma of the urinary bladder: The Memorial Sloan-Kettering experience. (2012) (0)
Abstract B20: Characterization of tumor mutational landscape in smokers and nonsmokers with urothelial carcinoma (2020) (0)
Reply by Authors. (2023) (0)
MP38-01 PRIMARY URETHRAL CANCER – TREATMENT PATTERNS AND ASSOCIATED OUTCOMES (2019) (0)
1487 PERSISTENT PROSTATE CANCER IN PATIENTS TREATED WITH PROSTATE RADIOTHERAPY WHO SUBSEQUENTLY UNDERGO RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER (2013) (0)
MP03-01 ROBOT-ASSISTED RADICAL CYSTECTOMY WITH EXTRACORPOREAL URINARY DIVERSION DOES NOT INCREASE URETEROENTERIC STRICTURE RATE: OUTCOMES FROM A RANDOMIZED TRIAL COMPARING OPEN VERSUS ROBOTIC CYSTECTOMY (2022) (0)
MP41-02 OUTCOMES OF NESTED VARIANT OF UROTHELIAL CARCINOMA FOLLOWING RADICAL CYSTECTOMY (2018) (0)
848: Predictive Utility of Urinary Cytologies for Non-Transitional Urothelial Malignancies (2005) (0)
MP41-07 LONGITUDINAL QUALITY OF LIFE EVALUATION AFTER RADICAL CYSTECTOMY: RESULTS OF A PROSPECTIVE STUDY (2021) (0)
Bladder Cancer after Renal Transplantation: 564 (2012) (0)
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. (2021) (0)
976: Clinical and Pathological Predictors of Pathologic Lymph Node Metastasis Identified during Nephroureterectomy for Transitional Cell Carcinoma of the Upper Urinary Tract (2005) (0)
Bladder Cancer: Invasive (III)Moderated Poster Session 641759 RISK FACTORS FOR THE DEVELOPMENT OF PARASTOMAL HERNIA AFTER RADICAL CYSTECTOMY (2013) (0)
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. (2021) (0)
Erratum to: Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings (2014) (0)
1106: Preoperative Urinary Cytology Predicts Disease Progression and Overall Survival after Nephroureterectomy for Transitional Cell Carcinoma of the Upper Urinary Tract (2006) (0)
MP63-13 TRIALS IN PROGRESS: A PHASE I/II TRIAL OF INTRAVESICAL CHEMOIMMUNOTHERAPY WITH GEMCITABINE AND BACILLUS CALMETTE-GUÉRIN (BCG) FOR PATIENTS WITH BCG-EXPOSED HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) (2023) (0)
673 THE IMPACT OF RESTAGING TUR ON OVERALL SURVIVAL IN PATIENTS WITH T1 TCC OF THE BLADDER (2009) (0)
PD10-03 HRQOL AFTER ROBOTIC-ASSISTED VERSUS OPEN RADICAL CYSTECTOMY: ANALYSIS OF A RCT (2022) (0)
Comment on: Can Restaging Transurethral Resection of T1 Bladder Cancer Select Patients for Immediate Cystectomy? Authors' reply (2007) (0)
Human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3) mutations to reveal biological pathways in urothelial carcinoma. (2022) (0)
A PROSPECTIVE STUDY ON THE IMPACT OF RADICAL CYSTECTOMY ON SEXUAL FUNCTION IN FEMALES WITH BLADDER CANCER: PD57‐10 (2017) (0)
MP50-16 MULTIPLE PRIMARY MALIGNANCIES IN RENAL CORTICAL NEOPLASMS: AN UPDATED EVALUATION (2015) (0)
Abstract LB-174: Examining the genomic differences between upper and lower tract urothelial carcinomas (2015) (0)
PD47-01 GENOMIC DETERMINANTS OF NESTED VARIANT UROTHELIAL CARCINOMA (2020) (0)
1593 CLINICAL MANAGEMENT OF MUSCLE INVASIVE MICROPAPILLARY BLADDER CANCER (2012) (0)
1381: Natural History and Clinical Importance of Positive Urinary Cytologies after a Radical Cystectomy for Transitional Cell Carcinoma (2005) (0)
PD66-07 ELECTRONIC RAPID FITNESS ASSESSMENT IDENTIFIES FACTORS ASSOCIATED WITH ADVERSE EARLY POSTOPERATIVE OUTCOMES FOLLOWING RADICAL CYSTECTOMY (2019) (0)
Using exon-capture, deep sequencing of high-grade bladder urothelial carcinoma to identify recurrent genetic alterations and potential therapeutic targets. (2014) (0)
Is restaging transurethral resection (TUR) necessary in patients with non-muscle invasive bladder cancer (NMIBC) and focal lamina propria invasion? (2017) (0)
Can excretory urography detect upper urinary tract tumors after radical cystectomy for urothelial cancer? (2008) (0)
PD47-02 “ACTIONABLE” GENOMIC ALTERATIONS IN CHEMOTHERAPY RESISTANT MUSCLE-INVASIVE BLADDER CANCER (2020) (0)
What to do when BCG fails (2008) (0)
MP27-12 PROGNOSTIC VALUE OF LYMPH NODE YIELD DURING NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA (2016) (0)
RECURRENCE AND PROGRESSION ACCORDING TO STAGE AT RE‐TUR IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BCG: NOT AS BAD AS PREVIOUSLY THOUGHT: PD48‐07 (2017) (0)
MP43-05 THE LANDSCAPE OF CLINICALLY ACTIONABLE GENOMIC ALTERATIONS IN PATIENTS WITH BACILLE CALMETTE-GUERIN (BCG) UNRESPONSIVE BLADDER CANCER: TOWARDS TARGETED THERAPY IN NON-MUSCLE INVASIVE BLADDER CANCER (2019) (0)
The ef fi cacy of BCG TICE and BCG Connaught in a cohort of 2 , 099 patients with T 1 G 3 non – muscle-invasive bladder cancer (2016) (0)
Treatment principles for nonmuscle invasive bladder cancer (2008) (0)
THE RISK OF PERSISTENT LOCAL DISEASE IN BLADDER CANCER PATIENTS FOUND TO BE PATHOLOGIC STAGE T0 AT RADICAL CYSTECTOMY (2008) (0)
PD55-01 A PROSPECTIVE SINGLE-BLINDED RANDOMIZED CONTROLLED CLINICAL TRIAL OF PERIOPERATIVE GOAL-DIRECTED FLUID THERAPY VERSUS STANDARD FLUID THERAPY FOR PATIENTS UNDERGOING OPEN RADICAL CYSTECTOMY ON A STANDARDIZED POSTOPERATIVE ENHANCED RECOVERY PATHWAY (2020) (0)
Cost-Effective Method t o Synthesize a Fluorescen t Internal DNA Standard for Automated Fragmen t (2001) (0)
A phase II trial of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin (BCG) for patients with BCG-exposed, high-grade, non-muscle–invasive bladder cancer. (2023) (0)
DEFECTIVE ERCC2 CONFERS INCREASED CISPLATIN AND IONIZING RADIATION SENSITIVITY IN BLADDER CANCER CELLS: MP98‐04 (2017) (0)
1905 ADHERENCE TO SURVEILLANCE GUIDELINES AFTER RADICAL CYSTECTOMY: A POPULATION-BASED ANALYSIS (2012) (0)
Results of high-dose-rate brachytherapy (HDR-BRT), anterior pelvic exenteration and external beam radiotherapy for female carcinoma of the urethra (2002) (0)
MP55-03 GENOMIC PREDICTORS OF PATHOLOGICAL UPSTAGING OF CLINICALLY LOCALIZED UROTHELIAL CARCINOMA AT RADICAL CYSTECTOMY (2020) (0)
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]. (2021) (0)
668 CONTEMPORARY OUTCOMES WITH PRIMARY MALE URETHRAL CARCINOMA (2012) (0)
Reply to Matthew Bultitude and Tim O’Brien’s Letter to the Editor re: Guido Dalbagni, Kinjal Vora, Matthew Kaag, et al. Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer. Eur Urol 2009;56:903–10 (2010) (0)
Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC). (2023) (0)
Reply from Author re: Vincenzo Serretta. T1HG Bladder Tumours: So Many Papers, Do We Need Them? Yes, We Do! Eur Urol 2009;56:911–3 (2009) (0)
1794 NON-NEOPLASTIC PARENCHYMAL CHANGES ASSOCIATED WITH RENAL CELL CARCINOMA (2013) (0)
1245: The Incidence and Risk Factors of Post-Operative Complications in Female Patients Undergoing Radical Cystectomy (2006) (0)
NEXT GENERATION SEQUENCING OF NON‐MUSCLE INVASIVE BLADDER CANCER REVEALS POTENTIAL BIOMARKERS AND RATIONAL THERAPEUTIC TARGETS: PD48‐11 (2017) (0)
PD55-08 INTRA-OPERATIVE URETERAL STENT USE AT RADICAL CYSTECTOMY IS ASSOCIATED WITH HIGHER 30-DAY COMPLICATIONS RATES (2020) (0)
PD44-04 AGE ASSOCIATED CHANGES TO HEALTH RELATED QUALITY OF LIFE AFTER RADICAL CYSTECTOMY: A PROSPECTIVE STUDY (2023) (0)
MP12-07 PROSPECTIVE HEALTH RELATED QUALITY OF LIFE IN WOMEN UNDERGOING RADICAL CYSTECTOMY AND URINARY DIVERSION (2023) (0)
LBA02-04 OUTCOMES AND GENOMIC CHARACTERISTICS OF NEWLY DIAGNOSED HIGH GRADE TA PAPILLARY UROTHELIAL CARCINOMA TREATED WITH INTRAVESICAL CHEMOTHERAPY VS BACILLUS CALMETTE GUERIN (BCG): A COMPARATIVE STUDY DURING THE BCG SHORTAGE (2023) (0)
PD47-05 PREVALENCE OF ACTIONABLE GENOMIC ALTERATIONS AND THE USE OF TARGETED THERAPY IN METASTATIC UROTHELIAL CARCINOMA (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Guido M. Dalbagni?

Guido M. Dalbagni is affiliated with the following schools:

Ohio State University

Guido M. Dalbagni's Academic­Influence.com Rankings

Why Is Guido M. Dalbagni Influential?

Guido M. Dalbagni's Published Works

Published Works

What Schools Are Affiliated With Guido M. Dalbagni?

Guido M. Dalbagni's AcademicInfluence.com Rankings